Abstract
Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P
| Original language | English |
|---|---|
| Pages (from-to) | 26-33 |
| Number of pages | 8 |
| Journal | Archives of Surgery |
| Volume | 138 |
| Issue number | 1 |
| State | Published - Jan 1 2003 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
Cite this
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. / Shen, Perry; Levine, Edward A.; Hall, Jason; Case, Doug; Russell, Greg; Fleming, Ronald; McQuellon, Richard; Geisinger, Kim R.; Loggie, Brian W.
In: Archives of Surgery, Vol. 138, No. 1, 01.01.2003, p. 26-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis
AU - Shen, Perry
AU - Levine, Edward A.
AU - Hall, Jason
AU - Case, Doug
AU - Russell, Greg
AU - Fleming, Ronald
AU - McQuellon, Richard
AU - Geisinger, Kim R.
AU - Loggie, Brian W.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P
AB - Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P
UR - http://www.scopus.com/inward/record.url?scp=0037228382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037228382&partnerID=8YFLogxK
M3 - Article
C2 - 12511145
AN - SCOPUS:0037228382
VL - 138
SP - 26
EP - 33
JO - JAMA Surgery
JF - JAMA Surgery
SN - 2168-6254
IS - 1
ER -